Limits...
IL-10 treatment is associated with prohibitin expression in the Crohn's disease intestinal fibrosis mouse model.

Yuan C, Chen WX, Zhu JS, Chen NW, Lu YM, Ou YX, Chen HQ - Mediators Inflamm. (2013)

Bottom Line: Fluorescence-based quantitative polymerase chain reaction (FQ-PCR) and immunohistochemistry assays revealed a significant upregulation of prohibitin with IL-10 treatment.Furthermore, IL-10 decreases inflammatory cytokines and TGF-β1 in the IL-10KO model of Crohn's disease and demonstrates a promising trend in decreasing tissue fibrosis.In conclusion, we hypothesize that IL-10 treatment is associated with increased prohibitin and would decrease inflammation and fibrosis in an animal model of Crohn's disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, China.

ABSTRACT
Prohibitin, which can inhibit oxidative stress and mitochondrial dysfunction, has been shown to have significant anti-inflammatory activities. Here, we investigate the effects of altering prohibitin levels in affected tissues in the interleukin-10 knockout (IL-10KO) mouse model with intestinal fibrosis. The aim of this study is to investigate the effects of IL-10 on prohibitin and the role of prohibitin in intestinal fibrosis of murine colitis. After the mice were treated with IL-10, prohibitin expression and localization were evaluated in IL-10KO and wild-type (WT, 129/SvEv) mice. The colon tissue was then investigated and the potential pathogenic molecular mechanisms were further studied. Fluorescence-based quantitative polymerase chain reaction (FQ-PCR) and immunohistochemistry assays revealed a significant upregulation of prohibitin with IL-10 treatment. Furthermore, IL-10 decreases inflammatory cytokines and TGF-β1 in the IL-10KO model of Crohn's disease and demonstrates a promising trend in decreasing tissue fibrosis. In conclusion, we hypothesize that IL-10 treatment is associated with increased prohibitin and would decrease inflammation and fibrosis in an animal model of Crohn's disease. Interestingly, prohibitin may be a potential target for intestinal fibrosis associated with inflammatory bowel disease (IBD).

Show MeSH

Related in: MedlinePlus

Effects of IL-10 on animal weight level in mice. Data were expressed as mean of weight values ± SD of 6 mice in each group. *P < 0.05 compared with control group; **P < 0.05 compared to the IL-10KO mice group.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3649775&req=5

fig1: Effects of IL-10 on animal weight level in mice. Data were expressed as mean of weight values ± SD of 6 mice in each group. *P < 0.05 compared with control group; **P < 0.05 compared to the IL-10KO mice group.

Mentions: There were significant differences in the mean weight of the control group, IL-10KO mice group, and IL-10-treated group in all of the experiments. The IL-10KO group exhibited a marked decrease in their body weight as compared to the control group at 12, 14, and 16 weeks (P < 0.05). The mice were sacrificed on wk 12, 14, and 16 and various degrees of edema and adhesion were found over the distal colon in a length of 3–5 cm and 1–3 cm in the model group and IL-10KO treatment group, respectively. Severe strictures associated with the dilatation of the proximal segment were exhibited gradually over time. In contrast, mice in the control group had only minimal inflammatory change. Administration of IL-10 led to a significant increase in body weight at 14 and 16 weeks as compared to the IL-10KO mice group (P < 0.05). At the end of study, the surviving mice in the IL-10-treated group gradually regained their weight but still failed to reach the initial weight (Figure 1).


IL-10 treatment is associated with prohibitin expression in the Crohn's disease intestinal fibrosis mouse model.

Yuan C, Chen WX, Zhu JS, Chen NW, Lu YM, Ou YX, Chen HQ - Mediators Inflamm. (2013)

Effects of IL-10 on animal weight level in mice. Data were expressed as mean of weight values ± SD of 6 mice in each group. *P < 0.05 compared with control group; **P < 0.05 compared to the IL-10KO mice group.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3649775&req=5

fig1: Effects of IL-10 on animal weight level in mice. Data were expressed as mean of weight values ± SD of 6 mice in each group. *P < 0.05 compared with control group; **P < 0.05 compared to the IL-10KO mice group.
Mentions: There were significant differences in the mean weight of the control group, IL-10KO mice group, and IL-10-treated group in all of the experiments. The IL-10KO group exhibited a marked decrease in their body weight as compared to the control group at 12, 14, and 16 weeks (P < 0.05). The mice were sacrificed on wk 12, 14, and 16 and various degrees of edema and adhesion were found over the distal colon in a length of 3–5 cm and 1–3 cm in the model group and IL-10KO treatment group, respectively. Severe strictures associated with the dilatation of the proximal segment were exhibited gradually over time. In contrast, mice in the control group had only minimal inflammatory change. Administration of IL-10 led to a significant increase in body weight at 14 and 16 weeks as compared to the IL-10KO mice group (P < 0.05). At the end of study, the surviving mice in the IL-10-treated group gradually regained their weight but still failed to reach the initial weight (Figure 1).

Bottom Line: Fluorescence-based quantitative polymerase chain reaction (FQ-PCR) and immunohistochemistry assays revealed a significant upregulation of prohibitin with IL-10 treatment.Furthermore, IL-10 decreases inflammatory cytokines and TGF-β1 in the IL-10KO model of Crohn's disease and demonstrates a promising trend in decreasing tissue fibrosis.In conclusion, we hypothesize that IL-10 treatment is associated with increased prohibitin and would decrease inflammation and fibrosis in an animal model of Crohn's disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, China.

ABSTRACT
Prohibitin, which can inhibit oxidative stress and mitochondrial dysfunction, has been shown to have significant anti-inflammatory activities. Here, we investigate the effects of altering prohibitin levels in affected tissues in the interleukin-10 knockout (IL-10KO) mouse model with intestinal fibrosis. The aim of this study is to investigate the effects of IL-10 on prohibitin and the role of prohibitin in intestinal fibrosis of murine colitis. After the mice were treated with IL-10, prohibitin expression and localization were evaluated in IL-10KO and wild-type (WT, 129/SvEv) mice. The colon tissue was then investigated and the potential pathogenic molecular mechanisms were further studied. Fluorescence-based quantitative polymerase chain reaction (FQ-PCR) and immunohistochemistry assays revealed a significant upregulation of prohibitin with IL-10 treatment. Furthermore, IL-10 decreases inflammatory cytokines and TGF-β1 in the IL-10KO model of Crohn's disease and demonstrates a promising trend in decreasing tissue fibrosis. In conclusion, we hypothesize that IL-10 treatment is associated with increased prohibitin and would decrease inflammation and fibrosis in an animal model of Crohn's disease. Interestingly, prohibitin may be a potential target for intestinal fibrosis associated with inflammatory bowel disease (IBD).

Show MeSH
Related in: MedlinePlus